

Dominique Costagliola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7546987/publications.pdf>

Version: 2024-02-01

534
papers

30,249
citations

4831

87
h-index

8433

152
g-index

556
all docs

556
docs citations

556
times ranked

22812
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129.	6.3	1,415
2	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. <i>PLoS Pathogens</i> , 2013, 9, e1003211.	2.1	879
3	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet, The</i> , 2009, 373, 1352-1363.	6.3	676
4	Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. <i>Journal of Experimental Medicine</i> , 2007, 204, 2473-2485.	4.2	655
5	Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies. <i>Clinical Infectious Diseases</i> , 2010, 50, 1387-1396.	2.9	525
6	Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. <i>Lancet Oncology, The</i> , 2009, 10, 1152-1159.	5.1	486
7	Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. <i>Aids</i> , 2003, 17, 2479-2486.	1.0	477
8	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	1.9	385
9	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	1.0	378
10	Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. <i>Blood</i> , 2001, 98, 2339-2344.	0.6	370
11	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010, 24, 123-137.	1.0	360
12	Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2000, 133, 401.	2.0	348
13	Incidence of Non-AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus-Infected Patients. <i>Journal of Clinical Oncology</i> , 2003, 21, 3447-3453.	0.8	345
14	Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. <i>International Journal of Epidemiology</i> , 2004, 34, 121-130.	0.9	321
15	Poly(lactic acid) implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients. <i>Aids</i> , 2003, 17, 2471-2477.	1.0	320
16	Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The Mortality in 2000 and 2005 Surveys (ANRS EN19 and Mortavic). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 590-598.	0.9	313
17	Rapid Progression to AIDS in HIV+ Individuals with a Structural Variant of the Chemokine Receptor CX3CR1. <i>Science</i> , 2000, 287, 2274-2277.	6.0	305
18	Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. <i>Journal of Hepatology</i> , 2005, 42, 799-805.	1.8	302

#	ARTICLE	IF	CITATIONS
19	Beyond viral suppression of HIV – the new quality of life frontier. <i>BMC Medicine</i> , 2016, 14, 94.	2.3	279
20	Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients; A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4. <i>Archives of Internal Medicine</i> , 2010, 170, 1228.	4.3	266
21	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.	1.0	264
22	Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. <i>Aids</i> , 2010, 24, 1228-1230.	1.0	256
23	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	3.9	256
24	Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. <i>Aids</i> , 2008, 22, 1203-1211.	1.0	240
25	Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. <i>Lancet</i> , The, 2003, 362, 679-686.	6.3	234
26	HIV and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 511-523.	1.2	234
27	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
28	Estimated Timing of Mother-to-Child Human Immunodeficiency Virus Type 1 (HIV-1) Transmission by Use of a Markov Model. <i>American Journal of Epidemiology</i> , 1995, 142, 1330-1337.	1.6	226
29	Causes of death among HIV-infected patients in France in 2010 (national survey). <i>Aids</i> , 2014, 28, 1181-1191.	1.0	223
30	Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2004, 101, 317-324.	2.0	216
31	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. <i>Aids</i> , 2009, 23, 817-824.	1.0	212
32	Comparison of Dynamic Treatment Regimes via Inverse Probability Weighting. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 237-242.	1.2	210
33	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet</i> , The, 2006, 368, 451-458.	6.3	209
34	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. <i>Aids</i> , 2015, 29, 221-229.	1.0	208
35	Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-Infected Individuals. <i>Blood</i> , 1999, 93, 936-941.	0.6	206
36	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. <i>Annals of Internal Medicine</i> , 2011, 154, 509.	2.0	205

#	ARTICLE	IF	CITATIONS
37	Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. <i>Aids</i> , 2002, 16, 727-736.	1.0	202
38	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 1743-1753.	1.0	200
39	Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4123-4128.	0.8	199
40	Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1459-1464.	1.0	186
41	Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. <i>International Journal of Epidemiology</i> , 2009, 38, 1624-1633.	0.9	173
42	Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. <i>Aids</i> , 2004, 18, 2029-2038.	1.0	168
43	Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. <i>Aids</i> , 2009, 23, 1163-1169.	1.0	165
44	Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. <i>Aids</i> , 2000, 14, 141-149.	1.0	160
45	When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data. <i>International Journal of Biostatistics</i> , 2010, 6, Article 18.	0.4	160
46	Changes in Cancer Mortality among HIV-Infected Patients: The Mortality 2005 Survey. <i>Clinical Infectious Diseases</i> , 2009, 48, 633-639.	2.9	147
47	Incidence of HIV-Related Anal Cancer Remains Increased Despite Long-Term Combined Antiretroviral Treatment: Results From the French Hospital Database on HIV. <i>Journal of Clinical Oncology</i> , 2012, 30, 4360-4366.	0.8	145
48	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	0.9	142
49	HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2012, 55, 600-607.	2.9	141
50	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. <i>Blood</i> , 2011, 117, 5142-5151.	0.6	140
51	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. <i>Aids</i> , 2011, 25, 1813-1822.	1.0	140
52	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
53	Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. <i>Aids</i> , 2008, 22, 1125-1129.	1.0	139
54	Incidence and Risk Factors for Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients before and during the Highly Active Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2001, 33, 1747-1755.	2.9	122

#	ARTICLE	IF	CITATIONS
55	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. <i>Aids</i> , 1999, 13, 2075-2082.	1.0	121
56	Combination of HIV-1-specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long-Term Nonprogression. <i>Journal of Infectious Diseases</i> , 2005, 191, 2053-2063.	1.9	121
57	HIV infection in older patients in the HAART era. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 4-7.	1.3	121
58	A routine tool for detection and assessment of epidemics of influenza-like syndromes in France.. <i>American Journal of Public Health</i> , 1991, 81, 97-99.	1.5	119
59	Semen alterations in HIV-1 infected men. <i>Human Reproduction</i> , 2002, 17, 2112-2118.	0.4	118
60	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. <i>Retrovirology</i> , 2009, 6, 49.	0.9	114
61	Evaluation of a peer support group therapy for HIV-infected adolescents. <i>Aids</i> , 2005, 19, 1501-1508.	1.0	112
62	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014, 83, 134-141.	1.5	112
63	Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion. <i>Journal of the National Cancer Institute</i> , 2010, 102, 784-792.	3.0	111
64	French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 545-552.	0.9	110
65	AIDS-Related Malignancies: State of the Art and Therapeutic Challenges. <i>Journal of Clinical Oncology</i> , 2008, 26, 4834-4842.	0.8	110
66	Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. <i>Journal of Experimental Medicine</i> , 2005, 201, 1999-2010.	4.2	105
67	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 473-478.	1.9	105
68	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	2.9	105
69	Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortality 2005 study. <i>Journal of Hepatology</i> , 2009, 50, 736-745.	1.8	102
70	Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. <i>International Journal of Cancer</i> , 2010, 126, 1724-1731.	2.3	102
71	Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans. <i>Journal of Immunology</i> , 2008, 180, 1482-1489.	0.4	101
72	Risk of triple-class virological failure in children with HIV: a retrospective cohort study. <i>Lancet</i> , The, 2011, 377, 1580-1587.	6.3	101

#	ARTICLE	IF	CITATIONS
73	Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. <i>Aids</i> , 2003, 17, 2635-2643.	1.0	100
74	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. <i>PLoS Medicine</i> , 2014, 11, e1001718.	3.9	100
75	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , 2011, 32, 41-50.	1.0	99
76	Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009. <i>Aids</i> , 2014, 28, 2109-2118.	1.0	99
77	Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. <i>Aids</i> , 2000, 14, 517-524.	1.0	98
78	Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 594-600.	1.4	96
79	Epidemiology of Toxoplasmosis among Pregnant Women in the Paris Area. <i>International Journal of Epidemiology</i> , 1988, 17, 595-602.	0.9	93
80	Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2010, 5, e13132.	1.1	93
81	Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalit� 2005 survey, ANRS) Tj ETQq1 1 0.784314 rgBT /Oerlock		
82	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 1065-1074.	0.6	92
83	Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial. <i>PLoS ONE</i> , 2010, 5, e10818.	1.1	92
84	Risk of AIDS-Defining Cancers Among HIV-1-Infected Patients in France Between 1992 and 2009: Results From the FHDH-ANRS CO4 Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 1638-1647.	2.9	92
85	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	2.9	92
86	The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 352-360.	0.9	90
87	Frequency, determinants and consequences of delayed access to care for HIV infection in France. <i>Antiviral Therapy</i> , 2007, 12, 89-96.	0.6	89
88	Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum Spots. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4441-4447.	1.8	88
89	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	2.9	88
90	Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. <i>Aids</i> , 1999, 13, 1881-1887.	1.0	85

#	ARTICLE	IF	CITATIONS
91	Predictors identified for losses to follow-up among HIV-seropositive patients. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 829-829.	2.4	85
92	Effect of Early Syphilis Infection on Plasma Viral Load and CD4 Cell Count in Human Immunodeficiency Virus-Infected Men. <i>Archives of Internal Medicine</i> , 2012, 172, 1237.	4.3	85
93	HIV Type 1-Specific IgG2 Antibodies: Markers of Helper T Cell Type 1 Response and Prognostic Marker of Long-Term Nonprogression. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1435-1446.	0.5	81
94	Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures. <i>Aids</i> , 2004, 18, 217-226.	1.0	78
95	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). <i>Aids</i> , 2008, 22, 1313-1322.	1.0	77
96	The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. <i>International Journal of Cancer</i> , 2011, 129, 467-475.	2.3	77
97	Demographics of HIV and aging. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 294-301.	1.5	77
98	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	2.8	77
99	Effect of Pioglitazone on HIV-1-Related Lipodystrophy: A Randomized Double-Blind Placebo-Controlled Trial (ANRS 113). <i>Antiviral Therapy</i> , 2008, 13, 67-76.	0.6	76
100	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	2.9	75
101	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	1.6	75
102	Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. <i>PLoS ONE</i> , 2015, 10, e0129550.	1.1	75
103	Impact of Highly Active Antiretroviral Therapy on the Incidence of Visceral Leishmaniasis in a French Cohort of Patients Infected with Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2002, 186, 1366-1370.	1.9	74
104	Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. <i>Aids</i> , 2010, 24, 77-83.	1.0	74
105	Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. <i>Aids</i> , 2002, 16, 2399-2407.	1.0	73
106	Observation plans in longitudinal studies with time-varying treatments. <i>Statistical Methods in Medical Research</i> , 2009, 18, 27-52.	0.7	73
107	Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. <i>Aids</i> , 2009, 23, 717-724.	1.0	73
108	The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. <i>Aids</i> , 2014, 28, 1797-1804.	1.0	72

#	ARTICLE	IF	CITATIONS
109	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. <i>Journal of Medical Virology</i> , 1999, 58, 256-263.	2.5	71
110	Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) 2010 survey. <i>HIV Medicine</i> , 2015, 16, 230-239.	1.0	71
111	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. <i>Aids</i> , 2013, 27, 803-813.	1.0	70
112	Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). <i>International Journal of Epidemiology</i> , 2014, 43, 1425-1436.	0.9	70
113	Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. <i>Aids</i> , 2016, 30, 761-769.	1.0	70
114	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	3.9	70
115	Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. <i>Neurology</i> , 1999, 53, 1197-1197.	1.5	69
116	Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1041-1049.	1.0	68
117	A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. <i>Aids</i> , 2015, 29, 2003-2007.	1.0	68
118	Patterns of Disclosure and Perceptions of the Human Immunodeficiency Virus in Infected Elementary School-age Children. <i>JAMA Pediatrics</i> , 1997, 151, 978.	3.6	67
119	Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 2027-2034.	1.0	67
120	What is known about the prevention of congenital toxoplasmosis?. <i>Lancet</i> , The, 1990, 336, 359-361.	6.3	65
121	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 2029-2037.	1.0	64
122	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	0.9	64
123	Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. <i>Clinical Infectious Diseases</i> , 2016, 62, 1297-1303.	2.9	64
124	GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*. <i>HIV Medicine</i> , 2004, 5, 352-359.	1.0	63
125	Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2008, 46, 296-304.	2.9	63
126	Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 10-20.	2.0	63

#	ARTICLE	IF	CITATIONS
127	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2620-2627.	1.3	62
128	HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. <i>Blood</i> , 2011, 118, 44-49.	0.6	62
129	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2015, 84, 632-633.	1.5	62
130	Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 482-487.	1.5	61
131	Clinically relevant interpretation of genotype for resistance to abacavir. <i>Aids</i> , 2003, 17, 1795-1802.	1.0	60
132	Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. <i>Aids</i> , 2006, 20, 1923-1930.	1.0	60
133	Comparing the public health burden of chronic hepatitis C and HIV infection in France. <i>Journal of Hepatology</i> , 2004, 40, 319-326.	1.8	59
134	Anticardiolipin Antibodies in HIV Infection Are Independently Associated with Antibodies to the Membrane Proximal External Region of gp41 and with Cell-Associated HIV DNA and Immune Activation. <i>Clinical Infectious Diseases</i> , 2009, 48, 123-132.	2.9	59
135	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. <i>Aids</i> , 2016, 30, 221-230.	1.0	59
136	Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. <i>HIV Medicine</i> , 2008, 9, 246-256.	1.0	58
137	Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e20967.	1.1	58
138	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, 1364-1372.	2.9	58
139	Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). <i>Aids</i> , 2002, 16, 486-488.	1.0	58
140	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. <i>Antiviral Therapy</i> , 2004, 9, 465-478.	0.6	58
141	Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement. <i>Journal of Clinical Oncology</i> , 2006, 24, 3408-3414.	0.8	57
142	Serum Ferritin, Desferrioxamine, and Evolution of HIV-1 Infection in Thalassemic Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 473-478.	0.3	56
143	Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. <i>Aids</i> , 2005, 19, 25-33.	1.0	56
144	Impact of Late Presentation on the Risk of Death Among HIV-Infected People in France (2003-2009). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 197-203.	0.9	54

#	ARTICLE	IF	CITATIONS
145	Timing of mother-to-child HIV-1 transmission depends on maternal status. <i>Aids</i> , 1993, 7, S49-52.	1.0	53
146	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. <i>Journal of Medical Virology</i> , 2006, 78, 153-160.	2.5	53
147	Do Tests Devised to Detect Recent HIV-1 Infection Provide Reliable Estimates of Incidence in Africa?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 115-122.	0.9	53
148	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	0.9	53
149	Progression to AIDS in French haemophiliacs. <i>Aids</i> , 1993, 7, 497-500.	1.0	52
150	High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 412-418.	0.9	52
151	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , 2015, 2, e335-e343.	2.1	52
152	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	2.9	52
153	Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. <i>Aids</i> , 2006, 20, 1627-1635.	1.0	51
154	Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. <i>BMC Infectious Diseases</i> , 2014, 14, 122.	1.3	51
155	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017, 31, 2493-2501.	1.0	51
156	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. <i>Journal of Infection</i> , 2007, 54, 367-374.	1.7	50
157	Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France. <i>Journal of the International AIDS Society</i> , 2018, 21, e25100.	1.2	50
158	Dose of desferrioxamine and evolution of HIV infection in thalassaemic patients. <i>British Journal of Haematology</i> , 1994, 87, 849-852.	1.2	49
159	Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. <i>HIV Medicine</i> , 2015, 16, 553-562.	1.0	49
160	Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4687-4692.	1.4	48
161	Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1762-1769.	2.9	48
162	Prevalence of HIV-1 Drug Resistance in Treated Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 12-18.	0.9	48

#	ARTICLE	IF	CITATIONS
163	Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method. <i>Aids</i> , 1997, 11, 1183-1184.	1.0	47
164	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. <i>Clinical Infectious Diseases</i> , 2015, 61, 1469-1475.	2.9	47
165	Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). <i>Vaccine</i> , 2005, 23, 4292-4301.	1.7	46
166	A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. <i>Journal of Medical Virology</i> , 2010, 82, 1819-1828.	2.5	46
167	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	2.9	46
168	Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016. <i>BMC Infectious Diseases</i> , 2020, 20, 728.	1.3	46
169	Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088). <i>Antiviral Therapy</i> , 2003, 8, 427-434.	0.6	46
170	A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. <i>Aids</i> , 1995, 9, 253-260.	1.0	45
171	No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. <i>Aids</i> , 2005, 19, 1643-1647.	1.0	45
172	Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy. <i>PLoS ONE</i> , 2010, 5, e11659.	1.1	45
173	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	1.0	45
174	Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. <i>Lung Cancer</i> , 2006, 54, 11-18.	0.9	44
175	Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 728-733.	1.4	44
176	New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data. <i>Aids</i> , 2011, 25, 1905-1913.	1.0	44
177	HIV-1 DNA Levels in Peripheral Blood Mononuclear Cells and Cannabis Use are Associated With Intermittent HIV Shedding in Semen of Men Who Have Sex With Men on Successful Antiretroviral Regimens. <i>Clinical Infectious Diseases</i> , 2014, 58, 1763-1770.	2.9	44
178	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
179	Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection. <i>Annals of Internal Medicine</i> , 1998, 129, 525.	2.0	43
180	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43

#	ARTICLE	IF	CITATIONS
181	The unrecognised French BSE epidemic. <i>Veterinary Research</i> , 2004, 35, 349-362.	1.1	43
182	Rates of Disease Progression according to Initial Highly Active Antiretroviral Therapy Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies. <i>Journal of Infectious Diseases</i> , 2006, 194, 612-622.	1.9	42
183	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	4.3	42
184	Incidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Therapy Era: Results From the FHDH-ANRS CO4 Cohort. <i>Clinical Infectious Diseases</i> , 2015, 60, 1269-1277.	2.9	42
185	Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. <i>International Journal of Epidemiology</i> , 2000, 29, 168-174.	0.9	41
186	Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. <i>Aids</i> , 2010, 24, 614-617.	1.0	41
187	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	4.6	41
188	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2626-2631.	1.3	41
189	Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. <i>Aids</i> , 2013, 27, 2425-2430.	1.0	41
190	Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1193-1196.	0.5	40
191	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009, 23, 2199-2208.	1.0	40
192	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011, 25, 27-36.	1.0	40
193	Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. <i>International Journal of Cancer</i> , 2015, 137, 2443-2453.	2.3	39
194	Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 348-355.	0.9	39
195	Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. <i>Aids</i> , 1998, 12, 1395-1397.	1.0	39
196	CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. <i>Aids</i> , 2018, 32, 2605-2614.	1.0	38
197	Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy? A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. <i>Aids</i> , 2001, 15, 1075-1077.	1.0	38
198	Survival after neuroAIDS. <i>Neurology</i> , 2011, 76, 644-651.	1.5	37

#	ARTICLE	IF	CITATIONS
199	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. <i>Annals of Oncology</i> , 2016, 27, 397-408.	0.6	37
200	HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. <i>Aids</i> , 2011, 25, 1017-1023.	1.0	37
201	Metabolic Syndrome in a French Cohort of Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1078-1085.	1.1	37
202	The Incubation Period of Kuru. <i>Epidemiology</i> , 2002, 13, 402-408.	1.2	36
203	Abacavir and Cardiovascular Risk: Reviewing the Evidence. <i>Current HIV/AIDS Reports</i> , 2010, 7, 127-133.	1.1	36
204	Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120). <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 972-980.	0.5	36
205	High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. <i>Aids</i> , 2011, 25, 1128-1131.	1.0	35
206	Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2004, 9, 315-323.	0.6	35
207	A 6-Month Interruption of Antiretroviral Therapy Improves Adipose Tissue Function in HIV-Infected Patients: The ANRS EP29 Lipostop Study. <i>Antiviral Therapy</i> , 2007, 12, 1273-1284.	0.6	35
208	Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a caseâ€“control study. <i>Aids</i> , 2001, 15, 2011-2016.	1.0	34
209	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	0.9	34
210	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. <i>PLoS ONE</i> , 2014, 9, e85516.	1.1	34
211	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. <i>Lancet HIV</i> , 2015, 2, e82-e91.	2.1	34
212	Prevalence of resistance mutations in antiretroviral-naïve chronically HIV-infected patients in 1998: a French nationwide study. <i>Aids</i> , 2001, 15, 1777-1782.	1.0	33
213	Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 284-292.	0.9	32
214	Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 556-561.	1.3	32
215	Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naïve individuals. <i>Aids</i> , 2014, 28, 1351-1356.	1.0	32
216	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV</i> , 2014, 1, e119-e126.	2.1	32

#	ARTICLE	IF	CITATIONS
217	High prevalence of Anal Human Papillomavirus-associated cancer precursors in a contemporary cohort of asymptomatic HIV-infected women. <i>Clinical Infectious Diseases</i> , 2015, 60, 1559-68.	2.9	32
218	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
219	Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). <i>Antiviral Therapy</i> , 2008, 13, 67-76.	0.6	31
220	Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. <i>Aids</i> , 2006, 20, 1795-1804.	1.0	30
221	NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically infected, ART-treated HIV patients. <i>European Journal of Immunology</i> , 2012, 42, 3038-3048.	1.6	30
222	Heterosexual Risk of HIV Transmission per Sexual Act Under Combined Antiretroviral Therapy: Systematic Review and Bayesian Modeling. <i>Clinical Infectious Diseases</i> , 2014, 59, 115-122.	2.9	30
223	Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. <i>Aids</i> , 2014, 28, 2677-2682.	1.0	30
224	Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. <i>Antiviral Therapy</i> , 2007, 12, 1305-1310.	0.6	30
225	Apparent Enhancement of Perinatal Transmission of Human Immunodeficiency Virus Type 1 by High Maternal Anti-gp160 Antibody Titer. <i>Journal of Infectious Diseases</i> , 1998, 177, 1737-1741.	1.9	29
226	Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. <i>HIV Medicine</i> , 2006, 7, 520-529.	1.0	29
227	A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipodystrophy. <i>HIV Clinical Trials</i> , 2010, 11, 39-50.	2.0	29
228	Twelve Months of Routine HIV Screening in 6 Emergency Departments in the Paris Area: Results from the ANRS URDEP Study. <i>PLoS ONE</i> , 2012, 7, e46437.	1.1	29
229	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1400-1405.	1.3	29
230	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1648-1652.	1.3	29
231	Can antiviral agents decrease the occurrence of Kaposi's sarcoma?. <i>Lancet, The</i> , 1995, 346, 578.	6.3	28
232	Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size. <i>Transfusion</i> , 1999, 39, 1141-1144.	0.8	28
233	Alterations of self-reactive antibody repertoires in HIV disease: An insight into the role of T cells in the selection of autoreactive B cells. <i>Immunology Letters</i> , 2005, 99, 198-208.	1.1	28
234	Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/ μ l. <i>Aids</i> , 2009, 23, 1997-2004.	1.0	28

#	ARTICLE	IF	CITATIONS
235	Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. <i>Aids</i> , 2011, 25, 115-118.	1.0	28
236	Single-Nucleotide Polymorphism-Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV Infection. <i>Journal of Infectious Diseases</i> , 2012, 205, 718-724.	1.9	28
237	Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1388-1399.	1.3	28
238	Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2016, 213, 1455-1461.	1.9	28
239	Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1-10.	0.5	28
240	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.4	28
241	Rotation of the cell nucleus in living cells: a quantitative analysis. <i>Biology of the Cell</i> , 1985, 54, 135-142.	0.7	28
242	Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial. <i>Antiviral Therapy</i> , 2002, 7, 211-218.	0.6	28
243	Time to AIDS From 1992 to 1999 in HIV-1-Infected Subjects With Known Date of Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 81-87.	0.9	27
244	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS) Tj ETQq0 0 QzBT /Overlock 10 T		
245	Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. <i>Epidemiology and Infection</i> , 2006, 134, 1345-1352.	1.0	27
246	HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. <i>Aids</i> , 2007, 21, 2243-2245.	1.0	27
247	Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 182-190.	0.7	27
248	Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access. <i>Clinical Infectious Diseases</i> , 2015, 60, 463-472.	2.9	27
249	Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. <i>Aids</i> , 2016, 30, 327-330.	1.0	27
250	Limited Impact of Immunosuppression and Haart on the Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Positive Women. <i>Antiviral Therapy</i> , 2006, 11, 1091-1096.	0.6	27
251	Contraceptive Use in HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 714-720.	0.9	26
252	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 357-363.	0.9	26

#	ARTICLE	IF	CITATIONS
253	Burden of HIV and hepatitis C infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. <i>Liver International</i> , 2015, 35, 65-70.	1.9	26
254	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2742-2751.	1.3	26
255	Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy. <i>Antiviral Therapy</i> , 2001, 6, 179-183.	0.6	26
256	Incubation time for AIDS from French transfusion-associated cases. <i>Nature</i> , 1989, 338, 768-769.	13.7	25
257	IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia. <i>Aids</i> , 2003, 17, 841-850.	1.0	25
258	Wild type and H43Y variant of human TRIM5 α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. <i>Immunogenetics</i> , 2007, 59, 511-515.	1.2	25
259	Imported Malaria in HIV-Infected Patients Enrolled in the ANRS CO4 FHDH Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 55-60.	0.9	25
260	Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalite 2000 & 2005' Surveys (ANRS EN19). <i>International Journal of Epidemiology</i> , 2010, 39, 135-146.	0.9	25
261	Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow-up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder [FACE-BD]). <i>Bipolar Disorders</i> , 2017, 19, 651-660.	1.1	25
262	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	1.3	25
263	CD4 ⁺ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 ⁺ T-cell counts >200 cells/mm ³ . <i>Antiviral Therapy</i> , 2009, 14, 451-457.	0.6	25
264	Initiation of Insulin Treatment after 70 Years of Age: Patient Status 2 Years Later. <i>Diabetic Medicine</i> , 1991, 8, 773-777.	1.2	24
265	How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalit� 2000 survey and death certificates [*] . <i>HIV Medicine</i> , 2009, 10, 236-245.	1.0	24
266	HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. <i>Aids</i> , 2010, 24, 763-771.	1.0	24
267	Relevance of EORTC Criteria for the Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival Trends Over a 20-Year Period in France. <i>Clinical Infectious Diseases</i> , 2015, 61, 1273-1280.	2.9	24
268	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. <i>American Heart Journal</i> , 2017, 183, 91-101.	1.2	24
269	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1 Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 292-300.	0.9	24
270	HIV-associated <i>Isospora belli</i> infection: incidence and risk factors in the French Hospital Database on HIV. <i>HIV Medicine</i> , 2007, 8, 124-130.	1.0	23

#	ARTICLE	IF	CITATIONS
271	Surgical management of cervical intraepithelial neoplasia in HIV-infected women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 141, 153-157.	0.5	23
272	Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 797-808.	1.3	23
273	Boosted protease inhibitor monotherapy as a maintenance strategy. <i>Aids</i> , 2012, 26, 2345-2350.	1.0	23
274	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 104-112.	0.7	23
275	Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. <i>Aids</i> , 2013, 27, 635-643.	1.0	23
276	CD4+/CD8 + ratio restoration in long-term treated HIV-1-infected individuals. <i>Aids</i> , 2017, 31, 1685-1695.	1.0	23
277	Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 109-115.	1.1	22
278	Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: Bayesian estimation using a mixture. , 1999, 18, 815-833.		22
279	Primary Prevention With Cotrimoxazole for HIV-1-Infected Adults: Results of the Pilot Study in Dakar, Senegal. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 130-136.	0.9	22
280	Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 16-20.	2.5	22
281	Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside Test. <i>Journal of the American College of Cardiology</i> , 2010, 55, 617-625.	1.2	22
282	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: Therapeutic implications. <i>European Journal of Cancer</i> , 2012, 48, 3335-3341.	1.3	22
283	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 214-221.	0.9	22
284	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017, 46, dyw211.	0.9	22
285	Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. <i>Vox Sanguinis</i> , 2001, 80, 199-204.	0.7	21
286	Clinical and Immunologic Outcome in Patients with Human Immunodeficiency Virus Infection, According to Virologic Efficacy in the Year after Virus Undetectability, during Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2003, 37, 1517-1526.	2.9	21
287	Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. <i>HIV Medicine</i> , 2008, 9, 625-635.	1.0	21
288	Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. <i>Aids</i> , 2013, 27, 401-406.	1.0	21

#	ARTICLE	IF	CITATIONS
289	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015, 29, 2323-2333.	1.0	21
290	Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial. <i>Annals of Emergency Medicine</i> , 2018, 72, 41-53.e9.	0.3	21
291	Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	21
292	Characteristics of the env Genes of HIV Type 1 Quasispecies in Long-Term Nonprogressors With Broadly Neutralizing Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 274-284.	0.9	20
293	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
294	Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 738-747.	1.3	20
295	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. <i>Aids</i> , 2019, 33, 133-143.	1.0	20
296	Epidemiology of Kaposi's Sarcoma. <i>Cancers</i> , 2021, 13, 5692.	1.7	20
297	The cost of diabetes in France. <i>Health Policy</i> , 1988, 9, 39-48.	1.4	19
298	Towards a new predictor of AIDS progression through the quantisation of HIV-1 DNA copies by PCR in HIV-infected individuals. <i>British Journal of Haematology</i> , 1992, 82, 467-471.	1.2	19
299	Modeling the Time Course of CD4 T-Lymphocyte Counts According to the Level of Virologic Rebound in HIV-1-Infected Patients on Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 50-57.	0.9	19
300	Prevalence of Low Bone Mineral Density in Men and Women Infected With Human Immunodeficiency Virus 1 and a Proposal for Screening Strategy. <i>Journal of Clinical Densitometry</i> , 2012, 15, 422-433.	0.5	19
301	Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2641-2648.	2.9	19
302	Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. <i>PLoS ONE</i> , 2017, 12, e0184441.	1.1	19
303	Cell cycle models and mother-daughter correlation. <i>Journal of Theoretical Biology</i> , 1988, 131, 255-262.	0.8	18
304	The prevalence of diabetes mellitus in the adult population of Guadeloupe as estimated by history or fasting hyperglycemia. <i>Diabetes Research and Clinical Practice</i> , 1991, 12, 209-216.	1.1	18
305	When is the epidemic warning cut-off point exceeded?. <i>European Journal of Epidemiology</i> , 1994, 10, 475-476.	2.5	18
306	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	1.0	18

#	ARTICLE	IF	CITATIONS
307	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. <i>Aids</i> , 2014, 28, 1683-1687.	1.0	18
308	Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported <i>Plasmodium falciparum</i> Malaria in France. <i>Clinical Infectious Diseases</i> , 2020, 70, 280-287.	2.9	18
309	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	2.9	18
310	A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. <i>Lancet HIV</i> , 2022, 9, e79-e90.	2.1	18
311	Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir. <i>Antiviral Therapy</i> , 2004, 9, 221-227.	0.6	18
312	Differences in androgens of HIV positive patients with and without Kaposi sarcoma.. <i>Journal of Clinical Pathology</i> , 1995, 48, 513-518.	1.0	17
313	Bivariate Longitudinal Model For The Analysis Of The Evolution Of Hiv Rna And Cd4 Cell Count In Hiv Infection Taking Into Account Left Censoring Of Hiv Rna Measures. <i>Journal of Biopharmaceutical Statistics</i> , 2003, 13, 271-282.	0.4	17
314	HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens: Table A1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3202-3205.	1.3	17
315	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	1.3	17
316	Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4). <i>Clinical Infectious Diseases</i> , 2018, 67, 275-282.	2.9	17
317	Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study. <i>American Journal of Transplantation</i> , 2019, 19, 3345-3355.	2.6	17
318	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020, 70, 2435-2438.	2.9	17
319	Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy. <i>Journal of Medical Virology</i> , 2003, 69, 401-407.	2.5	16
320	Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 644-647.	1.4	16
321	Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease. <i>Clinical Infectious Diseases</i> , 2012, 54, 408-413.	2.9	16
322	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	2.9	16
323	How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 32-39.	0.6	16
324	How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?. <i>Transfusion</i> , 1995, 35, 542-547.	0.8	15

#	ARTICLE	IF	CITATIONS
325	Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. <i>Psychological Medicine</i> , 2007, 37, 1315-1322.	2.7	15
326	Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort. <i>PLoS ONE</i> , 2015, 10, e0133358.	1.1	15
327	The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. <i>Haemophilia</i> , 2001, 7, 82-88.	1.0	15
328	Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. <i>Aids</i> , 2010, 24, 2323-2329.	1.0	15
329	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1-5.	2.8	15
330	A new approach to estimating AIDS incubation times: results in homosexual infected men.. <i>Journal of Epidemiology and Community Health</i> , 1992, 46, 582-586.	2.0	14
331	Relations between doppler tracings of pulmonary regurgitation and invasive hemodynamics in acute right ventricular infarction complicating inferior wall left ventricular infarction. <i>American Journal of Cardiology</i> , 1995, 75, 425-430.	0.7	14
332	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1362-1368.	1.3	14
333	Increased cardiovascular risk in HIV infection: drugs, virus and immunity. <i>Aids</i> , 2008, 22, 1625-1627.	1.0	14
334	Obesity in HIV-infected patients in France: Prevalence and surgical treatment options. <i>Journal of Visceral Surgery</i> , 2015, 152, 33-37.	0.4	14
335	Sleep quality, chronotype and metabolic syndrome components in bipolar disorders during the remission period: Results from the FACE-BD cohort. <i>Chronobiology International</i> , 2017, 34, 1114-1124.	0.9	14
336	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. <i>Journal of Psychiatric Research</i> , 2017, 94, 62-69.	1.5	14
337	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	1.0	14
338	Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. <i>International Journal of Cancer</i> , 2020, 146, 3134-3146.	2.3	14
339	Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients. <i>Statistics in Medicine</i> , 2003, 22, 1675-1690.	0.8	13
340	Trends in Post-Infection CD4 Cell Counts and Plasma HIV-1 RNA Levels in HIV-1 Infected Patients in France Between 1997 and 2005. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 422-426.	0.9	13
341	Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 54-61.	0.6	13
342	MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection. <i>Aids</i> , 2013, 27, 1707-1716.	1.0	13

#	ARTICLE	IF	CITATIONS
343	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 268-280.	2.9	13
344	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
345	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	0.9	13
346	Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). <i>Open AIDS Journal</i> , 2008, 2, 3-9.	0.1	13
347	A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e9-298.e15.	2.8	13
348	Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). <i>Antiviral Therapy</i> , 2003, 8, 427-34.	0.6	13
349	Usefulness of Pulmonary Regurgitation Doppler Tracings in Predicting In-Hospital and Long-Term Outcome in Patients With Inferior Wall Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1998, 81, 276-281.	0.7	12
350	Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. <i>Neurology</i> , 1998, 50, 565-566.	1.5	12
351	Evaluating therapeutic vaccines in patients infected with HIV. <i>Expert Review of Vaccines</i> , 2004, 3, S169-S177.	2.0	12
352	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 249-253.	0.9	12
353	CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression. <i>Journal of the International AIDS Society</i> , 2014, 17, 19481.	1.2	12
354	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	0.9	12
355	Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. <i>Journal of the International AIDS Society</i> , 2019, 22, e25371.	1.2	12
356	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 226-234.	2.5	12
357	HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e017578.	1.6	12
358	First-line Highly Active Antiretroviral Regimens in 2001-2002 in the French Hospital Database on HIV: Combination Prescribed and Biological Outcomes. <i>Antiviral Therapy</i> , 2007, 12, 317-324.	0.6	12
359	Lifelong variations in heart rates in SPF Sprague Dawley rats of both sexes. <i>Pflugers Archiv European Journal of Physiology</i> , 1979, 380, 189-195.	1.3	11
360	Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. <i>Journal of Pediatrics</i> , 1993, 122, 966-973.	0.9	11

#	ARTICLE	IF	CITATIONS
361	Pneumocystis carinii Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 151-158.	0.9	11
362	Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. <i>Aids</i> , 2006, 20, 2392-2395.	1.0	11
363	Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. <i>Aids</i> , 2006, 20, 2099-2106.	1.0	11
364	Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing Systems for Didanosine against Virological Response. <i>Journal of Infectious Diseases</i> , 2008, 198, 470-480.	1.9	11
365	Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status. <i>PLoS ONE</i> , 2019, 14, e0210253.	1.1	11
366	Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 50, 367-399.	0.8	11
367	Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. <i>Antiviral Therapy</i> , 2002, 7, 211-8.	0.6	11
368	Incidence of AIDS in HIV-1 infected thalassaemia patients. <i>British Journal of Haematology</i> , 1992, 81, 109-112.	1.2	10
369	Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma. <i>HIV Medicine</i> , 2000, 1, 232-237.	1.0	10
370	Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: A French nationwide study. <i>Journal of Medical Virology</i> , 2005, 76, 441-446.	2.5	10
371	Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase) Tj ETQq1 1 0.784314 rgBT /Overlock nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. <i>Aids</i> , 2009, 23, 1605-1608.	1.0	10
372	The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France. <i>Pharmacoeconomics</i> , 2010, 28, 59-68.	1.7	10
373	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 390-398.	0.9	10
374	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	2.1	10
375	Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (<sc>FHDH</sc>) Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (<sc>ANRS</sc>) CO4 cohort study. <i>HIV Medicine</i> , 2019, 20, 222-229.	1.0	10
376	Risk factors for loss to follow-up, transfer or death among people living with HIV on their first antiretroviral therapy regimen in Mali. <i>HIV Medicine</i> , 2019, 20, 47-53.	1.0	10
377	Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. <i>Aids</i> , 2020, 34, 1859-1862.	1.0	10
378	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. , 1999, 58, 256.		10

#	ARTICLE	IF	CITATIONS
379	Time to AIDS From 1992 to 1999 in HIV-1â€“Infected Subjects With Known Date of Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 81-87.	0.9	10
380	Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals. <i>Antiviral Therapy</i> , 2005, 10, 563-573.	0.6	10
381	Hemodynamic criteria for diagnosis of right ventricular ischemia associated with inferior wall left ventricular acute myocardial infarction. <i>American Journal of Cardiology</i> , 1995, 76, 220-225.	0.7	9
382	Is the AIDS incubation time changing? A back-calculation approach. , 1999, 18, 1031-1047.		9
383	Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. , 1999, 18, 1803-1817.		9
384	Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. <i>British Journal of Haematology</i> , 2002, 116, 383-389.	1.2	9
385	Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: Results from a randomized control trial. <i>Hepatology</i> , 2002, 35, 238-239.	3.6	9
386	How was the French BSE epidemic underestimated?. <i>Comptes Rendus - Biologies</i> , 2006, 329, 106-116.	0.1	9
387	Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 206-214.	0.9	9
388	Later cART Initiation in Migrant Men from Sub-Saharan Africa without Advanced HIV Disease in France. <i>PLoS ONE</i> , 2015, 10, e0118492.	1.1	9
389	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , 2016, 30, 879-888.	1.0	9
390	Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. <i>BMC Medical Research Methodology</i> , 2017, 17, 160.	1.4	9
391	Epsteinâ€“Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2019, 33, 993-1000.	1.0	9
392	Trajectories of functioning in bipolar disorders: A longitudinal study in the FondaMental Advanced Centers of Expertise in Bipolar Disorders cohort. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 985-996.	1.3	9
393	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. <i>Bulletin of the World Health Organization</i> , 2015, 93, 521-528.	1.5	9
394	CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4+ T-cell counts >200 cells/mm ³ . <i>Antiviral Therapy</i> , 2009, 14, 451-7.	0.6	9
395	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9
396	Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000. <i>European Journal of Epidemiology</i> , 2006, 21, 389-396.	2.5	8

#	ARTICLE	IF	CITATIONS
397	Estimating incidence of the French BSE infection using a joint analysis of both asymptomatic and clinical BSE surveillance data. <i>Mathematical Biosciences</i> , 2007, 209, 90-107.	0.9	8
398	Complementary Approach of Data Analysis and Modeling to Estimate the Pattern of the BSE Epidemic: The Example of France. <i>Risk Analysis</i> , 2007, 27, 1141-1150.	1.5	8
399	Antiretroviral-naïve and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 566-572.	1.3	8
400	Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France. <i>Aids</i> , 2016, 30, 2235-2246.	1.0	8
401	Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 214-223.	0.9	8
402	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	2.9	8
403	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/μL. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	1.2	8
404	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 764-765.	4.6	8
405	Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third. <i>Vox Sanguinis</i> , 1990, 59, 248-250.	0.7	7
406	Epstein-Barr virus transactivator antibodies in HIV infection. <i>Lancet</i> , The, 1991, 338, 574.	6.3	7
407	Cumulative incidence of HIV infection and AIDS case prediction in France. <i>Lancet</i> , The, 1993, 342, 436-437.	6.3	7
408	<i>Pneumocystis carinii</i> Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 151-158.	0.9	7
409	IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy—results from the ANRS CO4 cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2215-2223.	1.3	7
410	Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France. <i>Pharmacoeconomics</i> , 2010, 28, 183-197.	1.7	7
411	Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1869-1877.	1.3	7
412	Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. <i>Aids</i> , 2012, 26, 1801-1805.	1.0	7
413	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
414	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naïve patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2252-2261.	1.3	7

#	ARTICLE	IF	CITATIONS
415	Time for a revolution in tracking the HIV epidemic. <i>Lancet HIV</i> , 2016, 3, e337-e339.	2.1	7
416	Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial. <i>HIV Medicine</i> , 2019, 20, 202-213.	1.0	7
417	Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 547-551.	0.9	7
418	Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 607-615.	0.4	7
419	Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS CO4 French Hospital Database on HIV cohort. <i>HIV Medicine</i> , 2020, 21, 180-188.	1.0	7
420	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020, 34, 599-608.	1.0	7
421	Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. <i>Journal of Infectious Diseases</i> , 2020, 221, 516-522.	1.9	7
422	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". <i>American Journal of Epidemiology</i> , 2020, 189, 1443-1444.	1.6	7
423	Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017. <i>Eurosurveillance</i> , 2021, 26, .	3.9	7
424	Long-Term Nonprogression in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 409-411.	0.3	7
425	Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. <i>Cells</i> , 2022, 11, 1015.	1.8	7
426	Incubation time for AIDS. <i>Nature</i> , 1987, 328, 582-582.	13.7	6
427	Epidemiologic comparison of human T-lymphotropic virus type I-infected blood donors from endemic and nonendemic regions over a 3-year period. <i>Transfusion</i> , 1994, 34, 198-201.	0.8	6
428	X.Pneumocystis and pneumocystosis in Europe at the end of the 20th century. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 22, 87-91.	2.7	6
429	Risk-Benefit Analysis of Nucleic Acid Testing: The French Experience. <i>Biologicals</i> , 1999, 27, 343-348.	0.5	6
430	Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. <i>Journal of Infectious Diseases</i> , 2004, 190, 675-687.	1.9	6
431	National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. <i>Journal of Medical Virology</i> , 2008, 80, 762-765.	2.5	6
432	Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. <i>HIV Medicine</i> , 2008, 9, 27-40.	1.0	6

#	ARTICLE	IF	CITATIONS
433	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 451-455.	1.3	6
434	Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2012, 17, 855-860.	0.6	6
435	Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19070.	1.2	6
436	Boosted Lopinavir Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2015, 60, 1262-1268.	2.9	6
437	GBD 2013 and HIV incidence in high income countries. <i>Lancet, The</i> , 2015, 385, 1177.	6.3	6
438	Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3339-3344.	1.3	6
439	Cancers in elite controllers. <i>Aids</i> , 2016, 30, 1852-1855.	1.0	6
440	Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3305-3314.	1.3	6
441	Critical Importance of Long-Term Adherence to Care in HIV Infected Patients in the cART Era: New Insights from <i>Pneumocystis jirovecii</i> Pneumonia Cases over 2004-2011 in the FHDH-ANRS CO4 Cohort. <i>PLoS ONE</i> , 2014, 9, e94183.	1.1	6
442	Risk Factors for Seborrheic Dermatitis Flares: Case-control and Case-crossover Study. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00292.	0.6	6
443	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4³ Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). <i>Antiviral Therapy</i> , 2003, 8, 233-237.	0.6	6
444	No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. <i>Aids</i> , 2003, 17, 1394-1396.	1.0	5
445	Nevirapine-associated toxicity in Niger. <i>HIV Medicine</i> , 2008, 9, 62-63.	1.0	5
446	Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. <i>Aids</i> , 2010, 24, 365-371.	1.0	5
447	Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 138-144.	1.3	5
448	Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 752-760.	1.3	5
449	Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. <i>Aids</i> , 2015, 29, 853-856.	1.0	5
450	Which adults in the Paris metropolitan area have never been tested for HIV? A 2010 multilevel, cross-sectional, population-based study. <i>BMC Infectious Diseases</i> , 2015, 15, 278.	1.3	5

#	ARTICLE	IF	CITATIONS
451	Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Clinical Infectious Diseases</i> , 2016, 63, ciw498.	2.9	5
452	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3172-3176.	1.3	5
453	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2862-2868.	1.3	5
454	Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France. <i>Neurology</i> , 2018, 91, e724-e731.	1.5	5
455	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020, 188, 413-423.	1.2	5
456	Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. <i>European Journal of Cancer</i> , 2020, 138, 189-192.	1.3	5
457	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection. <i>Annals of Internal Medicine</i> , 2020, 172, 297.	2.0	5
458	Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. <i>Aids</i> , 2021, 35, 861-868.	1.0	5
459	Do people living with HIV face more secondary cancers than general population: From the French CANCEVIH network. <i>Bulletin Du Cancer</i> , 2021, 108, 908-914.	0.6	5
460	L'introduction de la PCR dans le dépistage du virus de l'hépatite C dans les dons de sang : du mésusage du principe de précaution. <i>Medecine/Sciences</i> , 2001, 17, 344.	0.0	5
461	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 445-454.	1.3	5
462	First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. <i>Antiviral Therapy</i> , 2007, 12, 317-24.	0.6	5
463	Estimation of the Size of the HIV/AIDS Epidemic due to Blood Transfusion in France. <i>International Journal of Epidemiology</i> , 1995, 24, 441-445.	0.9	4
464	Comparative Biological and Clinical Outcomes after a Switch from a Virologically Unsuccessful First Protease Inhibitor-Containing Antiretroviral Combination to a 3-Drug Regimen Containing Efavirenz, Nevirapine, or Abacavir. <i>Clinical Infectious Diseases</i> , 2007, 44, 120-127.	2.9	4
465	A Step Ahead on the HIV Collaboratory. <i>Science</i> , 2009, 324, 1264-1265.	6.0	4
466	Early initiation of treatment for HIV infection. <i>Lancet, The</i> , 2010, 375, 639.	6.3	4
467	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2487-2493.	1.3	4
468	β-Blocker Use for Patients With or at Risk for Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 438.	3.8	4

#	ARTICLE	IF	CITATIONS
469	The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial. <i>BMC Infectious Diseases</i> , 2015, 16, 51.	1.3	4
470	Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors. <i>Comptes Rendus - Biologies</i> , 2017, 340, 109-113.	0.1	4
471	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS 163 ETRAL Study. <i>Pharmacotherapy</i> , 2019, 39, 514-520.	1.2	4
472	Utility of Epstein-Barr Virus Biomarkers in Human Immunodeficiency Virus-related Lymphomas in the Modern Combined Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2019, 68, 891-892.	2.9	4
473	Re-engagement in care of people living with HIV lost to follow-up after initiation of antiretroviral therapy in Mali: Who returns to care?. <i>PLoS ONE</i> , 2020, 15, e0238687.	1.1	4
474	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	1.7	4
475	Pharmacological data of a successful 4â€daysâ€week regimen in HIV antiretroviral therapy (ANRS 162â€4D) Tj ETQq1 1 0,784314	1.1	4
476	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.0	4
477	Lamivudine and Indinavir/Ritonavir Maintenance Therapy in Highly Pretreated HIV-Infected Patients (Vista Anrs 109). <i>Antiviral Therapy</i> , 2006, 11, 889-900.	0.6	4
478	Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals. <i>Aids</i> , 1992, 6, 1405.	1.0	3
479	Zidovudine in Patients with HIV Infection. <i>Annals of Internal Medicine</i> , 1996, 124, 372.	2.0	3
480	Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma.. <i>Journal of Clinical Pathology</i> , 1997, 50, 341-345.	1.0	3
481	Decreased Peripheral Circulation of HIV-Infected Cells in a Subset of Long-Term Nonprogressors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 21, 253.	0.9	3
482	Didanosine Dosed Once Daily Is Equivalent to Twice Daily Dosing for Patients on Double or Triple Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 24, 418-424.	0.9	3
483	BSE Risk Assessment as a Basis for Updating French Screening Policy. <i>Risk Analysis</i> , 2007, 27, 1131-1140.	1.5	3
484	One or two enzyme-linked immunosorbent assay tests on the first serum sample for initial diagnosis of HIV-1 infection?. <i>Aids</i> , 2008, 22, 2042-2044.	1.0	3
485	Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in the Combination Antiretroviral Therapy Era and Predictors of Discontinuation or Switch to Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 206-211.	0.9	3
486	HEPATITIS B VACCINE AND THE RISK OF CNS INFLAMMATORY DEMYELINATION IN CHILDHOOD. <i>Neurology</i> , 2009, 73, 1426-1427.	1.5	3

#	ARTICLE	IF	CITATIONS
487	Interobserver variability of cervical cytology in HIV-infected women. <i>Cytopathology</i> , 2015, 26, 362-367.	0.4	3
488	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. <i>Medicine (United States)</i> , 2016, 95, e5133.	0.4	3
489	Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 467-476.	1.3	3
490	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 214-223.	0.5	3
491	Can HIV epidemics among MSM be eliminated through participation in preexposure prophylaxis rollouts?. <i>Aids</i> , 2021, 35, 2347-2354.	1.0	3
492	Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-1-Infected Individuals. <i>Blood</i> , 1999, 93, 936-941.	0.6	3
493	Revealing HIV epidemic dynamics and contrasting responses in two WHO Eastern European countries: insights from modeling and data triangulation. <i>Aids</i> , 2021, 35, 675-680.	1.0	3
494	Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. <i>Antiviral Therapy</i> , 2005, 10, 563-73.	0.6	3
495	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS122011945.	1.4	3
496	Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. <i>Comptes Rendus - Biologies</i> , 2007, 330, 347-355.	0.1	2
497	Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 468-474.	0.9	2
498	Performance of Quantiferon® for the diagnosis TB. <i>Médecine Et Maladies Infectieuses</i> , 2012, 42, 579-584.	5.1	2
499	Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3356-3359.	1.3	2
500	Risk of HIV Transmission Under Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e41-e42.	0.9	2
501	Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice. <i>PLoS ONE</i> , 2015, 10, e0144746.	1.1	2
502	A Multifaceted Intervention Designed to Improve Medical Management of Moderate to Advanced Chronic Kidney Disease in HIV-Infected Patients: A Cluster Randomized Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 375-384.	2.9	2
503	Impact of migration origin on individual protection strategies against sexual transmission of HIV in Paris metropolitan area, SIRS cohort study, France. <i>BMC Public Health</i> , 2015, 15, 807.	1.2	2
504	Survival in individuals living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 451-454.	1.5	2

#	ARTICLE	IF	CITATIONS
505	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 490-496.	1.3	2
506	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 102-109.	0.9	2
507	Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. <i>BMC Infectious Diseases</i> , 2018, 18, 326.	1.3	2
508	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3699-3700.	1.3	2
509	COVID-19: individual and herd immunity. <i>Comptes Rendus - Biologies</i> , 2021, 344, 7-18.	0.1	2
510	Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma. <i>Cancers</i> , 2022, 14, 128.	1.7	2
511	BEDSIDE ESTIMATION OF MICROALBUMINURIA. <i>Lancet, The</i> , 1986, 327, 268-269.	6.3	1
512	A rational attitude toward serum alanine aminotransferase measurement by blood banks, based on a longitudinal study of a cohort of repeat blood donors. <i>Transfusion</i> , 1991, 31, 201-204.	0.8	1
513	Épidémiologie du cancer de l'anus. <i>Cancéro Digest</i> , 2011, , .	0.0	1
514	Undiagnosed HIV prevalence in France. <i>Aids</i> , 2012, 26, 2419.	1.0	1
515	Risk of cancers in HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 275-276.	0.3	1
516	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, e86-e87.	0.9	1
517	Tackling latency as a barrier to an HIV cure: what next?. <i>Lancet HIV, the</i> , 2015, 2, e504-e505.	2.1	1
518	Myocardial Infarction in HIV-Infected Persons: Time to Focus on the Silent Elephant in the Room?. <i>Clinical Infectious Diseases</i> , 2015, 60, 1424-5.	2.9	1
519	Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. <i>PLoS ONE</i> , 2018, 13, e0205385.	1.1	1
520	Factors Influencing the Incubation of an Infectious Form of Creutzfeldt-Jakob Disease. <i>Clinical Infectious Diseases</i> , 2019, 70, 1487-1490.	2.9	1
521	Routine screening for HIV , hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery. <i>HIV Medicine</i> , 2019, 20, 353-358.	1.0	1
522	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	1.3	1

#	ARTICLE	IF	CITATIONS
523	Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 784-786.	1.0	1
524	Impact of opportunistic diseases on survival in HIV-infected patients in France, 1992-1997. <i>Aids</i> , 1999, 13, 1789.	1.0	1
525	SMBG in NIDDM Patients Treated by General Practitioners in France. <i>Diabetes Care</i> , 1990, 13, 454-454.	4.3	0
526	Estimation of the number of HIV-seropositive patients known to general practitioners in France. <i>Aids</i> , 1994, 8, 1190.	1.0	0
527	HIV Incidence Estimates Among Women of Childbearing Age in the Area Around Paris, France: No Evidence for Any Effect of Age or Time. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 492-498.	0.9	0
528	On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients. <i>Aids</i> , 2006, 20, 2118-2120.	1.0	0
529	Is The Age-Period-Cohort Model Well Suited to an Epidemic Context? The Case of the French BSE Epidemic. <i>Statistical Communications in Infectious Diseases</i> , 2012, 4, .	0.2	0
530	Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals?. <i>Aids</i> , 2014, 28, 1987-1989.	1.0	0
531	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. <i>Aids</i> , 2015, 29, 857.	1.0	0
532	Risk of Severe Bacterial Infection in People Living Human Immunodeficiency Virus Infection in the Combined Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2020, 222, 765-776.	1.9	0
533	Visual Versus Instrumental Perception of Haze--A Review. <i>Technical Quarterly</i> , 2008, , .	1.0	0
534	R�le de lâ€™enveloppe GP 41 dans la pr�paration d�un candidat vaccin contre le VIH. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2009, 193, 127-138.	0.0	0